Browse
Submit Data
Databases
API
Help

Dataset Information

14 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II Study of XELOX and Cetuximab as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer

ABSTRACT: Interventions: Capecitabine+oxaliplatin(XELOX)+Cetuximab Cetuximab loading dose 400mg/m2, 250mg/m2/week or 500mg/m2/2weeks Capecitabine 2000mg/m2(day1-7)/2weeks Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2622614 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Multicenter Phase II Study of FOLFOX/XELOX and Erbitux as First Line Therapy in Patients with Wild Type KRAS/BRAF Metastatic Colorectal Cancer.

Project description:Interventions: Cetuximab 500mg/m2/bi-week(day1) Oxaliplatin 85mg/m2/bi-week(day1) l-LV 200 mg/m2/bi-week(day1) 5-FU/bolus 400mg/m2/bi-week bolus(day1) 5-FU/infusional 2400mg/m2/bi-week(day1-3) Cetuximab 500mg/m2/bi-week(day1) Oxaliplatin 85mg/m2/bi-week(day1) Capecitabine 2000mg/m2/day1-7.bi-wekly Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2618714 | ecrin-mdr-crc

Phase II clinical trial of Cetuximab with Fluorouracil therapy for patients refractory or intolerable to Oxaliplatin and Irinotecan with KRAS wild-type unresectable/recurrent colorectal cancer

Project description:Interventions: (Cetuximab with Fluorouracil therapy) Cetuximab=400mg/m2 (day1)Cetuximab=250mg/m2/weekly(day 8-) with 1) l-LV=200mg/m2/bi-week 5-FU/bolus=400mg/m2/bi-week 5-FU/infusional=2,400mg/m2/bi-week (day1-3) 2) LV=75mg/day (*Administration for 4weeks and Drug withdrawal for one week)UFT=300-600mg/day* 3) Capecitabine=2,000mg/m2/day(*Administration for 2weeks and Drug withdrawal for one week) 4) S-1=80-120mg/day (*Administration for 2weeks and Drug withdrawal for one week) Primary outcome(s): Progression-free survival; PFS Study Design: Single arm Non-randomized

| 2623785 | ecrin-mdr-crc

mFOLFOX6+Cetuximab in Treating Patients With not Optimally Resectable Liver Metastases From Colorectal Cancer

Project description:Interventions: mFOLFOX6Cetuximab Neoadjuvant 6course Adjuvant 6course Cetuximab loading dose 400mg/m2 weekly 250mg/m2/week LOHP 85mg/m2/day1 lLV 200mg/m2/day1 bolus 5FU 400mg/m2/day1 infusional 5FU 2400mg/m2/day1-3 Primary outcome(s): overall response rate Study Design: Single arm Non-randomized

| 2620254 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

Phase II Study of bi-weekly SOX+Cetuximab for EGFR positive and K-ras wild type dvanced and recurrent Colorectal Cancer

Project description:Interventions: Oxaliplatin:85mg/m2/week iv, day1.15 q 4weeks Cetuximab:day1 400, day8 250, day15 500mg/m2, day15- q 2weeks S-1:80mg/m2, day1-14 q 4weeks Primary outcome(s): Response ratte : RR Study Design: Single arm Non-randomized

| 2621320 | ecrin-mdr-crc

Early tumor shrinkage of Cetuximab and mFOLFOX6 in RAS-wild type unresectable metastatic colorectal cancer.

Project description:Interventions: Weekly Cetuximab+mFOLFOX6 Cetuximab 400mg/m2/ initial 250mg/m2/ qw Oxaliplatin 85mg/m2/ qw l-LV 200mg/m2/ qw 5FU-bols 400mg/m2/ qw 5FU-infusional 2,400mg/m2/ qw OR Biweekly Cetuximab+mFOLFOX6 Cetuximab 500mg/m2/ q2w Oxaliplatin 85mg/m2/ q2w l-LV 200mg/m2/ q2w 5FU-bols 400mg/m2/ q2w 5FU-infusional 2,400mg/m2/ q2w Primary outcome(s): ETS(Early Tumor Shrinkage) rate Study Design: Single arm Non-randomized

| 2630670 | ecrin-mdr-crc

Phase I study of TS-1+irinotecan+cetuximab as the first-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: Cetuximab 400mg/m2 Day1, 250mg/m2 Day 8, 15 Irinotecan 100-150mg/m2/Day1 S-1 80-120mg/day Day1-14 Primary outcome(s): Recommended Dose Study Design: Single arm Non-randomized

| 2626021 | ecrin-mdr-crc

Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal Cancer

Project description:Interventions: cetuximab S-1 combination therapy cetuximab : Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) S-1 : 60 or 80 mg/m2/2weeks/day1-14, 4weeks Primary outcome(s): To determine the recomend dose of cetuximab and S-1 combinaton therapy Study Design: Single arm Non-randomized

| 2619576 | ecrin-mdr-crc

Feasibility study of adjuvant chemotherapy with FOLFOX(or XELOX) for 3 months followed by oral anticancer drug for 3 months in patients with completely resected colorectal cancer

Project description:Interventions: mFOLFOX6 therapy(or XELOX therapy) for 3 months followed by capecitabine for 3 months mFOLFOX6 therapy Day1 L-OHP 85mg/m2,l-LV 200mg/m2 Day1 bolus 5FU 400mg/m2 Day1~2 Infusional 5FU 2400mg/m2 XELOX therapy Day1 L-OHP 130mg/m2 Day1~14(b.i.d. at the end of meal) capecitabine 2000mg/m2/day Capecitabine therapy Day1~14(b.i.d. at the end of meal) Capecitabine 2500mg/m2/day Primary outcome(s): Frequency and Grade of peripheral neuropathy(CTCAE v4 and PNQ) Study Design: Single arm Non-randomized

| 2620377 | ecrin-mdr-crc

A prospective study comparing targeted anticancer drug + irinotecan and targeted anticancer drug + 5-Fluorouracil / Leucovorin as maintenance treatment after primary induction chemotherapy for metastatic colorectal cancer

Project description:Interventions: Drug : This randomized phase 2 clinical trial aims to evaluate the effect of the Bevacizumab/Cetuximab+Irinotecan group compared to the Bevacizumab/Cetuximab+5-fluorouracil/Leucovorin group as maintenance therapy. Administer according to the recommended dosage regimen or the standard of the local institution Experomental group Bevacizumab or Cetuximab + Irinotecan, control group Bevacizumab or Cetuximab + 5 fluorouracil therapy every 2 weeks Recommended dose for Experomental group : Bevacizumab 5mg kg IV Day1, Cetuximab 500mg/m2 IV Day1 , Irinotecan 180mg/m2 IV Day1 Recommended dose of control group: Bevacizumab 5mg kg IV Day1, Cetuximab 500mg/m2 IV Day1,Leucovorin 400mg/m2 IV Day1, 5-fluorouracil 400mg/m2 IV bolus Day1 , 5-fluorouracil 2,400mg/m2 IV Day1-2 Primary outcome(s): Percentage of patients with progression-free status after secondary chemotherapy at one year from random assignment 1yr-PFS2 rate Primary Purpose : Treatment, Intervention Model : Parallel, Blinding/Masking : Open, Allocation : RCT

| 74818 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data